**Trader consensus heavily favors "No" (87.5% implied probability) because the existing October 2024 technology evaluation agreement between Eli Lilly and Peptron remains strictly non-binding and limited to joint research on applying SmartDepot microsphere technology to Lilly’s peptide candidates, including GLP-1 agents and expanded CNS indications.** This setup grants only a non-exclusive internal R&D license, allows Lilly to terminate on 30 days’ notice, and explicitly excludes commercial rights. The evaluation period, originally about 14 months and later extended to a maximum of 24 months, ends October 7, 2026, yet no binding technology transfer, commercial licensing, or equivalent agreement has been announced despite ongoing in-vivo studies and initial validation data shared by Peptron. Lilly has pursued alternative long-acting delivery platforms, such as its separate pact with Camurus for FluidCrystal technology targeting incretin therapies, creating competitive overlap that reduces urgency for SmartDepot. Recent developments, including Peptron’s September 2026 construction contract for a second Osong plant targeting 2028 completion and CEO comments on completed early validation plus broadened research scope, signal preparation for potential future partnerships but do not indicate an imminent commercial deal by the tight deadline. Market-implied odds reflect this uncertainty: a full licensing agreement would require a decisive shift from evaluation to commercialization within weeks, an outcome unsupported by official disclosures or credible reporting as of mid-September 2026.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于13% 概率
$11,414 交易量
$11,414 交易量
2026-10-06
13% 概率
$11,414 交易量
$11,414 交易量
2026-10-06
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.**Trader consensus heavily favors "No" (87.5% implied probability) because the existing October 2024 technology evaluation agreement between Eli Lilly and Peptron remains strictly non-binding and limited to joint research on applying SmartDepot microsphere technology to Lilly’s peptide candidates, including GLP-1 agents and expanded CNS indications.**
This setup grants only a non-exclusive internal R&D license, allows Lilly to terminate on 30 days’ notice, and explicitly excludes commercial rights. The evaluation period, originally about 14 months and later extended to a maximum of 24 months, ends October 7, 2026, yet no binding technology transfer, commercial licensing, or equivalent agreement has been announced despite ongoing in-vivo studies and initial validation data shared by Peptron.
Lilly has pursued alternative long-acting delivery platforms, such as its separate pact with Camurus for FluidCrystal technology targeting incretin therapies, creating competitive overlap that reduces urgency for SmartDepot. Recent developments, including Peptron’s September 2026 construction contract for a second Osong plant targeting 2028 completion and CEO comments on completed early validation plus broadened research scope, signal preparation for potential future partnerships but do not indicate an imminent commercial deal by the tight deadline.
Market-implied odds reflect this uncertainty: a full licensing agreement would require a decisive shift from evaluation to commercialization within weeks, an outcome unsupported by official disclosures or credible reporting as of mid-September 2026.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
市场开放时间： May 5, 2026, 8:02 PM ET
交易量
$11,414结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETThis market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.**Trader consensus heavily favors "No" (87.5% implied probability) because the existing October 2024 technology evaluation agreement between Eli Lilly and Peptron remains strictly non-binding and limited to joint research on applying SmartDepot microsphere technology to Lilly’s peptide candidates, including GLP-1 agents and expanded CNS indications.**
This setup grants only a non-exclusive internal R&D license, allows Lilly to terminate on 30 days’ notice, and explicitly excludes commercial rights. The evaluation period, originally about 14 months and later extended to a maximum of 24 months, ends October 7, 2026, yet no binding technology transfer, commercial licensing, or equivalent agreement has been announced despite ongoing in-vivo studies and initial validation data shared by Peptron.
Lilly has pursued alternative long-acting delivery platforms, such as its separate pact with Camurus for FluidCrystal technology targeting incretin therapies, creating competitive overlap that reduces urgency for SmartDepot. Recent developments, including Peptron’s September 2026 construction contract for a second Osong plant targeting 2028 completion and CEO comments on completed early validation plus broadened research scope, signal preparation for potential future partnerships but do not indicate an imminent commercial deal by the tight deadline.
Market-implied odds reflect this uncertainty: a full licensing agreement would require a decisive shift from evaluation to commercialization within weeks, an outcome unsupported by official disclosures or credible reporting as of mid-September 2026.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
交易量
$11,414结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ET**Trader consensus heavily favors "No" (87.5% implied probability) because the existing October 2024 technology evaluation agreement between Eli Lilly and Peptron remains strictly non-binding and limited to joint research on applying SmartDepot microsphere technology to Lilly’s peptide candidates, including GLP-1 agents and expanded CNS indications.** This setup grants only a non-exclusive internal R&D license, allows Lilly to terminate on 30 days’ notice, and explicitly excludes commercial rights. The evaluation period, originally about 14 months and later extended to a maximum of 24 months, ends October 7, 2026, yet no binding technology transfer, commercial licensing, or equivalent agreement has been announced despite ongoing in-vivo studies and initial validation data shared by Peptron. Lilly has pursued alternative long-acting delivery platforms, such as its separate pact with Camurus for FluidCrystal technology targeting incretin therapies, creating competitive overlap that reduces urgency for SmartDepot. Recent developments, including Peptron’s September 2026 construction contract for a second Osong plant targeting 2028 completion and CEO comments on completed early validation plus broadened research scope, signal preparation for potential future partnerships but do not indicate an imminent commercial deal by the tight deadline. Market-implied odds reflect this uncertainty: a full licensing agreement would require a decisive shift from evaluation to commercialization within weeks, an outcome unsupported by official disclosures or credible reporting as of mid-September 2026.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题